- Home
- MREO
as 11-21-2024 4:00pm EST
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
| Founded: | 2015 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 577.6M | IPO Year: | N/A |
| Target Price: | $7.50 | AVG Volume (30 days): | 769.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.86 - $5.02 | Next Earning Date: | 11-12-2024 |
| Revenue: | $1,000,000 | Revenue Growth: | -89.64% |
| Revenue Growth (this year): | 16.39% | Revenue Growth (next year): | 9.44% |
Stock Insider Trading Activity of Mereo BioPharma Group plc (MREO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Scots-Knight Denise | MREO | Chief Executive Officer | Sep 12 '24 | Sell | $4.35 | 88,657 | $381,422.59 | 868,967 | |
| Fox Christine Ann | MREO | Chief Financial Officer | Sep 12 '24 | Sell | $4.35 | 28,286 | $121,692.72 | 89,285 | |
| Sermon Charles | MREO | General Counsel | Sep 12 '24 | Sell | $4.35 | 30,926 | $133,050.61 | 240,007 | |
| Hughes-Wilson Alexandra | MREO | See Remarks | Sep 12 '24 | Sell | $4.35 | 148,110 | $637,203.07 | 190,816 | |
| Lewicki John A. | MREO | Chief Scientific Officer | Sep 12 '24 | Sell | $4.35 | 16,149 | $69,476.79 | 78,630 |
Latest Mereo BioPharma Group plc News
MREO Breaking Stock News: Dive into MREO Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
GlobeNewswire
9 days ago
Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Insider Monkey
a month ago
Is Mereo BioPharma Group (MREO) the Hottest Penny Stock to Invest in According to Hedge Funds?
Insider Monkey
2 months ago
Mereo BioPharma Group plc (MREO): A Bull Case Theory
GlobeNewswire
2 months ago
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference
GlobeNewswire
3 months ago
Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Argus Research
5 months ago
Daily – Vickers Top Buyers & Sellers for 07/01/2024
Argus Research
5 months ago
Daily – Vickers Top Buyers & Sellers for 06/28/2024
Compare MREO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MREO Mereo BioPharma Group plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.